SU-4942（Cat No.:I009618）is a small-molecule tyrosine kinase inhibitor primarily studied for its potential to target signaling pathways involved in cancer progression. It selectively inhibits specific receptor tyrosine kinases (RTKs), disrupting downstream pathways such as MAPK and PI3K/AKT that are critical for tumor cell proliferation, survival, and angiogenesis. SU-4942 has shown promise in preclinical models for its anti-tumor and anti-angiogenic effects, making it a candidate for further investigation in oncology research. Its targeted action offers the potential for reduced systemic toxicity compared to traditional chemotherapeutics, supporting its role in precision medicine strategies.